- Acinetobacter Baumanii
- Citrobacter Freundii
- Citrobacter Koseri
- Enterobacter Aerogenes
- Enterobacter Cloacae
- Escherichia Coli
- Klebsiella Oxytoca
- Klebsiella Pneumoniae
- Morganella Morganii
- Proteus Mirabilis
- Providencia Stuartii
- Pseudomonas Aeruginosa
- Serratia Marcescens
- Stenotrophomonas Maltophilia
NOTES:
- 69% of Haemophilus infuenzae isolates were beta lactamase negative (122 isolates tested). Beta Lactamase negative indicates probable susceptibility to penicillin, ampicillin and 1st generation cephalosporins. Beta lactamase positive indicates probable resistance to ampicillin, amoxicillin and first generation cephalosporins. Recommended therapy is combination therapy or a third generation cephalosporin.
- 100% of Moraxella (Branhamella) catarrhalis were beta lactamase positive (32 isolates tested). Beta lactamase positive indicates resistance to penicillin, ampicillin and first generation cephalosporins. Several beta-lactams are effective including beta lactam/Beta Lactamase inhibitory combinations, 3rd generation cephalosporins, macrolides, quinolones and trimethoprim/sulfamethoxazole.
- 40 isolates of Salmonella species and 10 Shigella species were recovered. Susceptibility testing is not routinely performed on intestinal sites. Extraintestinal sites are tested against ampicillin, trimethoprim/sulfa and a third generation cephalosporin. Intestinal source isolates will be tested per telephone request.
- 11 Campylobacter species were isolated in 2008.
- 5 Giardia lamblia positive rapid antigens were confirmed in 2008.
- 0 Cryptosporidium positive rapid antigens were confirmed in 2008.
Acinetobacter Baumanii
Number of Isolates: 48
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | • | • |
| Ampicillin/Sulbactam | 88 | 4 |
| Cefazolin | • | • |
| Cefepime | 40 | 29 |
| Ceftazidime | 29 | 9 |
| Ceftriaxone | • | • |
| Ciprofloxacin | 33 | 0 |
| Ertapenem | • | • |
| Gentamicin | 52 | 6 |
| Imipenem | 81 | 9 |
| Levofloxacin | 33 | 13 |
| Piperacillin/Tazobactam | • | • |
| Tobramycin | 90 | 10 |
| Trimethoprim/Sulfa | 31 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Citrobacter Freundii
Number of Isolates: 9
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | 0 | 0 |
| Cefepime | 89 | 0 |
| Ceftazidime | 67 | 0 |
| Ceftriaxone | 67 | 11 |
| Ciprofloxacin | 78 | 0 |
| Ertapenem | 89 | 0 |
| Gentamicin | 89 | 0 |
| Imipenem | 100 | |
| Levofloxacin | 78 | 0 |
| Piperacillin/Tazobactam | • | • |
| Tobramycin | 100 | |
| Trimethoprim/Sulfa | 78 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Citrobacter Koseri
Number of Isolates: 6
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | 100 | |
| Cefepime | 100 | |
| Ceftazidime | 100 | |
| Ceftriaxone | 100 | |
| Ciprofloxacin | 50 | 0 |
| Ertapenem | 100 | |
| Gentamicin | 100 | 0 |
| Imipenem | 100 | |
| Levofloxacin | 50 | 0 |
| Piperacillin/Tazobactam | • | • |
| Tobramycin | 100 | |
| Trimethoprim/Sulfa | 50 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Enterobacter Aerogenes
Number of Isolates: 12
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | 0 | |
| Cefepime | 100 | |
| Ceftazidime | 83 | 0 |
| Ceftriaxone | 83 | 17 |
| Ciprofloxacin | 100 | |
| Ertapenem | 100 | |
| Gentamicin | 92 | 0 |
| Imipenem | 100 | |
| Levofloxacin | 100 | |
| Piperacillin/Tazobactam | 92 | 8 |
| Tobramycin | 92 | 8 |
| Trimethoprim/Sulfa | 92 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Enterobacter Cloacae
Number of Isolates: 58
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 98 | 0 |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | 0 | |
| Cefepime | 97 | 1 |
| Ceftazidime | 66 | 1 |
| Ceftriaxone | 67 | 5 |
| Ciprofloxacin | 67 | 2 |
| Ertapenem | 81 | 14 |
| Gentamicin | 93 | 2 |
| Imipenem | 98 | 0 |
| Levofloxacin | 69 | 2 |
| Piperacillin/Tazobactam | 71 | 17 |
| Tobramycin | 83 | 10 |
| Trimethoprim/Sulfa | 86 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Escherichia Coli
Number of Isolates: 192
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | 48 | 12 |
| Cefazolin | 85 | 3 |
| Cefepime | 95 | 0 |
| Ceftazidime | 93 | 1 |
| Ceftriaxone | 94 | 1 |
| Ciprofloxacin | 58 | 1 |
| Ertapenem | 99 | 0 |
| Gentamicin | 85 | 1 |
| Imipenem | 99 | 0 |
| Levofloxacin | 58 | 1 |
| Piperacillin/Tazobactam | 99 | 0 |
| Tobramycin | 86 | 12 |
| Trimethoprim/Sulfa | 68 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Klebsiella Oxytoca
Number of Isolates: 20
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | 95 | |
| Cefazolin | 85 | 5 |
| Cefepime | 100 | |
| Ceftazidime | 100 | |
| Ceftriaxone | 100 | |
| Ciprofloxacin | 100 | |
| Ertapenem | 100 | |
| Gentamicin | 100 | |
| Imipenem | 100 | |
| Levofloxacin | 100 | |
| Piperacillin/Tazobactam | 100 | |
| Tobramycin | 100 | |
| Trimethoprim/Sulfa | 100 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Klebsiella Pneumoniae
Number of Isolates: 77
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 99 | 0 |
| Ampicillin/Sulbactam | 87 | 3 |
| Cefazolin | 96 | 0 |
| Cefepime | 97 | 0 |
| Ceftazidime | 97 | 0 |
| Ceftriaxone | 97 | 0 |
| Ciprofloxacin | 92 | 2 |
| Ertapenem | 100 | |
| Gentamicin | 97 | 2 |
| Imipenem | 100 | |
| Levofloxacin | 94 | 2 |
| Piperacillin/Tazobactam | 99 | 0 |
| Tobramycin | 96 | 3 |
| Trimethoprim/Sulfa | 91 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Morganella Morganii
Number of Isolates: 31
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | 0 | |
| Cefazolin | 0 | |
| Cefepime | 100 | |
| Ceftazidime | 55 | 32 |
| Ceftriaxone | 100 | |
| Ciprofloxacin | 74 | 7 |
| Ertapenem | 100 | |
| Gentamicin | 84 | 3 |
| Imipenem | • | • |
| Levofloxacin | 84 | 6 |
| Piperacillin/Tazobactam | 100 | |
| Tobramycin | 94 | 3 |
| Trimethoprim/Sulfa | 45 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Proteus Mirabilis
Number of Isolates: 214
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | 69 | 18 |
| Cefazolin | 95 | 1 |
| Cefepime | 96 | 0 |
| Ceftazidime | 96 | 0 |
| Ceftriaxone | 96 | 0 |
| Ciprofloxacin | 38 | 3 |
| Ertapenem | 100 | |
| Gentamicin | 78 | 16 |
| Imipenem | • | • |
| Levofloxacin | 44 | 5 |
| Piperacillin/Tazobactam | 100 | |
| Tobramycin | 92 | 8 |
| Trimethoprim/Sulfa | 47 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Providencia Stuartii
Number of Isolates: 33
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | 0 | |
| Cefazolin | 0 | |
| Cefepime | 97 | 0 |
| Ceftazidime | 82 | 3 |
| Ceftriaxone | 97 | 3 |
| Ciprofloxacin | 15 | 15 |
| Ertapenem | • | • |
| Gentamicin | 48 | 43 |
| Imipenem | • | • |
| Levofloxacin | 24 | 9 |
| Piperacillin/Tazobactam | 97 | 0 |
| Tobramycin | 48 | 49 |
| Trimethoprim/Sulfa | 55 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Pseudomonas Aeruginosa
Number of Isolates: 245
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 96 | 3 |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | • | • |
| Cefepime | 79 | 13 |
| Ceftazidime | 80 | 10 |
| Ceftriaxone | N/A | N/A |
| Ciprofloxacin | 56 | 5 |
| Ertapenem | • | • |
| Gentamicin | 82 | 7 |
| Imipenem | 78 | 11 |
| Levofloxacin | 55 | 7 |
| Piperacillin/Tazobactam | 94 | 0 |
| Tobramycin | 89 | 2 |
| Trimethoprim/Sulfa | • | • |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Serratia Marcescens
Number of Isolates: 35
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | 100 | |
| Ampicillin/Sulbactam | • | • |
| Cefazolin | 0 | |
| Cefepime | 100 | |
| Ceftazidime | 100 | |
| Ceftriaxone | 100 | |
| Ciprofloxacin | 97 | 3 |
| Ertapenem | 100 | |
| Gentamicin | 100 | |
| Imipenem | 100 | |
| Levofloxacin | 100 | |
| Piperacillin/Tazobactam | 100 | |
| Tobramycin | 97 | 3 |
| Trimethoprim/Sulfa | 97 | 0 |
● = Antibiotic not recommended due to lack of correlation between in vitro results and in vivo activity.
NA = Not Applicable
Back to Top
Stenotrophomonas Maltophilia
Number of Isolates: 35
| Antibiotic | Percent |
Percent Intermediate |
|---|---|---|
| Amikacin | N/A | N/A |
| Ampicillin/Sulbactam | N/A | N/A |
| Cefazolin | N/A | N/A |
| Cefepime | N/A | N/A |
| Ceftazidime | N/A | N/A |
| Ceftriaxone | N/A | N/A |
| Ciprofloxacin | N/A | N/A |
| Ertapenem | N/A | N/A |
| Gentamicin | N/A | N/A |
| Imipenem | N/A | N/A |
| Levofloxacin | N/A | N/A |
| Piperacillin/Tazobactam | N/A | N/A |
| Tobramycin | N/A | N/A |
| Trimethoprim/Sulfa | 89 | 0 |